Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback